- Company — Cerebral, Inc.
- Sector — Telehealth / mental health
- Founded / Died — 2019 / survives in reduced form; the company as constituted ended 2022–2024
- Lifespan — Ongoing
- Capital raised — ~$462M (SoftBank Vision Fund 2, Access Industries, Oak HC/FT); peak valuation $4.8B (December 2021)
- Peak scale — Reported >200,000 active patients and ~4,500 staff at peak; revenue reported in the hundreds of millions annualised (company-stated).
- What it built — Subscription telehealth for anxiety, depression and — critically — ADHD, with prescribing of controlled stimulants under COVID-era telehealth flexibilities.
- Stated cause of death — Cerebral has never declared failure. Founder-CEO Kyle Robertson was removed by the board in May 2022 amid a federal prescribing investigation; the company then exited controlled-substance prescribing, cut most of its staff, and repositioned.
- Evidenced cause — Regulatory, squarely. In November 2024 Cerebral agreed to pay roughly $3.65M to DOJ (about $6.6M including related penalties) over unlawful distribution of controlled substances, following a $7M FTC settlement over cancellation practices and a data breach affecting 3.1 million people. The underlying condition: growth driven by advertising that funnelled patients toward stimulant prescriptions under a temporary regulatory waiver, with clinician time per patient reportedly compressed to unsafe levels. When DEA scrutiny arrived, the growth engine was the liability.
- Warning signs visible earlier — Internal clinician complaints reported from 2021. Pharmacies (CVS, Walmart) stopped filling Cerebral prescriptions in May 2022. The temporary nature of the telehealth waiver was public policy, not a surprise.
- Money outcome — SoftBank and later investors are very heavily impaired. Thousands of employees lost jobs across 2022–23. Patients on controlled-substance treatment faced abrupt discontinuation. Robertson was sued by his own company over a loan and later led another telehealth venture that itself drew FTC and DOJ action in 2026.
- Post-mortem quality — None; litigation forecloses it. This is a general rule: where there is enforcement exposure, there is no post-mortem.
- Transferable lesson — If your growth depends on a temporary regulatory accommodation, you have a business with a published end date.
- Sources — DOJ press release · Healthcare Dive · Forbes on the CEO's removal
Read the wider evidence
This entry is reproduced from the supplied research, with its inline source links retained. It has not been independently re-reported for this website conversion.
Read the complete chapter, source list, and methodological notes →